A Continuation Clinical Trial of Every Three-Week Dosing of Oral ONC201 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 02 Feb 2017
At a glance
- Drugs ONC 201 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 19 Jan 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2019.
- 14 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Mar 2017.
- 25 Feb 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.